SYnAbs' vision is to fill the gap in the marketplace for innovative mAbs against poor immunogenic compounds and complex antigens. Targeting steroids, peptides, small molecules, toxins, lipids and polysaccharides, SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.
Custom monoclonal antibody services
An unique one-stop-shop from animal housing to custom manufacturing up to several grams!
Multiple species antibody experts
Maximizing the success rate and the quality of the mAbs generated in rats and guinea pigs.
The benefits of our technology?
- Extreme specificity
- Higher affinity
- Excellent results for small, difficult and poor immunogenic antigens
- Additional epitope recognition
- Access to the lymph nodes
- Rat Fc close to the human one
- Ideal for mice antigens
Our 2018 agenda
| When? | Where? |
|
Jan 30th - Jan 31rst February 1rst Feb 7th - Feb 8th Mar12th - Mar 13th Apr 2nd - Apr 4th May 18th May 15th - May 17th June 4th - June 7th June 19th - June 20th June 27th - June 28th July 29th - Aug 2nd Sep 26th - Sep 27th Oct 31rst - Nov 2nd Nov 12th - Nov 15th Nov 12th - Nov 16th Dec 4th |
Berlin, Germany, CAR-T Congress Europe Rotterdam, The Netherlands, Innovation for Health Gosselies, Belgium, Buzz4Bio Cell&Gene Therapies Amsterdam, The Netherlands, BioEurope Spring Singapore, Singapore, Medlab Asia Ghent, Belgium, Knowledge 4 Growth Tel Aviv, Israël, BioMed Boston, USA, BIO Oxford, United Kingdom, Pivotal Scientific Genève, Switzerland, A3P Bioproduction Chicago, USA, AACC Vilnius, Lituany, Lifesciences Baltics Brisbane, Australia, AusBiotech Dusseldorf, Germany, MEDICA Lisbon, Portugal, PEGS Louvain-la-Neuve, Belgium, Biowin Day |